Tofacitinib for Pityriasis Rubra Pilaris: A Case Report [PDF]
Hongyan Tan, Bin Zhang, Xiawei Kang, Lvyao Wang, Xiao Qiu, Xiangyu Hu Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People’s Republic of ChinaCorrespondence: Xiangyu Hu, Email 369930758@qq.comPurpose ...
Tan H +5 more
doaj +6 more sources
Oral Alitretinoin for the Treatment of Recalcitrant Pityriasis Rubra Pilaris [PDF]
Treatment of pityriasis rubra pilaris is still challenging. We here present a 74-year-old woman who had not experienced stable remission of her skin symptoms during prior treatments including topical and systemic corticosteroids, phototherapy, orally ...
Laurenz Schmitt +2 more
doaj +6 more sources
Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report [PDF]
Pityriasis rubra pilaris is a rare inflammatory dermatosis characterized by orange-red confluent plaques, hyperkeratotic follicular papules, palmoplantar keratoderma, and, in some cases, erythroderma.
Mysa Saad, Alison Spurr, Jennifer Lipson
doaj +3 more sources
Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review [PDF]
BackgroundPityriasis rubra pilaris is a chronic, scaly, keratotic skin disease, mainly manifested as scaly plaques and keratinized hair follicles. This condition significantly impacts the patient’s quality of life and is considered one of the intractable
Xiaofang Zhang +7 more
doaj +5 more sources
Targeting IL-1 controls refractory pityriasis rubra pilaris. [PDF]
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis ...
Schmauch E +22 more
europepmc +4 more sources
Updates on Pityriasis Rubra Pilaris: A Scoping Review. [PDF]
Pityriasis rubra pilaris (PRP) is a rare, inflammatory papulosquamous skin disease with unknown exact etiology. Historically, PRP has been challenging to diagnose, especially during the acute phase, and to treat, due to its unclear pathogenesis.
Zhou T, Al Muqrin A, Abu-Hilal M.
europepmc +4 more sources
Loss-of-function mutations in Keratin 32 gene disrupt skin immune homeostasis in pityriasis rubra pilaris. [PDF]
Pityriasis rubra pilaris (PRP) is an inflammatory papulosquamous dermatosis, characterized by hyperkeratotic follicular papules and erythematous desquamative plaques. The precise pathogenic mechanism underlying PRP remains incompletely understood. Herein,
Shi P +23 more
europepmc +4 more sources
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris. [PDF]
Pityriasis rubra pilaris (PRP) is a rare, papulosquamous, inflammatory skin disease. PRP represents a therapeutic challenge. The rarity of this disease and its possible spontaneous remission makes the conduction and interpretation of therapeutic studies ...
Potestio L +8 more
europepmc +3 more sources
Refractory pityriasis rubra pilaris treated with upadacitinib [PDF]
Eingun James Song, MD +2 more
doaj +3 more sources
Pityriasis rubra pilaris presenting with an abnormal autoimmune profile: two case reports [PDF]
Introduction Pityriasis rubra pilaris is an uncommon inflammatory and hyperproliferative dermatosis of juvenile or adult onset. The etiology of the disease is still unknown.
Gregoriou Stamatis +5 more
doaj +4 more sources

